The pan-histone deacetylase inhibitor LBH589 (panobinostat) alters the invasive breast cancer cell phenotype

By            

International Journal of Oncology, Vol. 44, Iss. 3, 2014-01 ,pp. : 700-708

Spandidos Publications

Access to resources Recommend Favorite

The pan-deacetylase inhibitor panobinostat affects angiogenesis in hepatocellular carcinoma models via modulation of CTGF expression

By                          

International Journal of Oncology, Vol. 47, Iss. 3, 2015-01 ,pp. : 963-970

Spandidos Publications

Access to resources Recommend Favorite

The pan-DAC inhibitor LBH589 is a multi-functional agent in breast cancer cells: cytotoxic drug and inducer of sodium-iodide symporter (NIS)

By Fortunati N.   Catalano M.   Marano F.   Mugoni V.   Pugliese M.   Bosco O.   Mainini F.   Boccuzzi G.  

Breast Cancer Research and Treatment, Vol. 124, Iss. 3, 2010-12 ,pp. : 667-675

Springer Publishing Company

Access to resources Recommend Favorite

The pandeacetylase inhibitor panobinostat modulates the expression of epithelialmesenchymal transition markers in hepatocellular carcinoma models

By                

Oncology Letters, Vol. 5, Iss. 1, 2013-01 ,pp. : 127-134

Spandidos Publications

Access to resources Recommend Favorite

A Phase II Trial of Panobinostat, a Histone Deacetylase Inhibitor, in the Treatment of Patients with Refractory Metastatic Renal Cell Carcinoma

By Hainsworth John D.   Infante Jeffrey R.   Spigel David R.   Arrowsmith Edward R.   Boccia Ralph V.   Burris Howard A.  

Cancer Investigation, Vol. 29, Iss. 7, 2011-07 ,pp. : 451-455

Informa Healthcare

Access to resources Recommend Favorite